- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04246047
Evaluering af effektivitet og sikkerhed af Belantamab Mafodotin, Bortezomib og Dexamethason versus Daratumumab, Bortezomib og Dexamethason hos deltagere med recidiverende/refraktær myelomatose (DREAMM 7)
DRØMME 7: Et multicenter, åbent, randomiseret fase III-studie til evaluering af effektiviteten og sikkerheden af kombinationen af Belantamab Mafodotin, Bortezomib og Dexamethason (B-Vd) sammenlignet med kombinationen af Daratumumab, Bortezomib og Dexamethason (D-Vdhason) ) hos deltagere med recidiverende/refraktær myelomatose
This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Udvidet adgang
Kontakter og lokationer
Studiesteder
-
-
New South Wales
-
Camperdown, New South Wales, Australien, 2050
- GSK Investigational Site
-
Liverpool, New South Wales, Australien, 2170
- GSK Investigational Site
-
Newcastle, New South Wales, Australien, 2298
- GSK Investigational Site
-
St Leonards, New South Wales, Australien, 2065
- GSK Investigational Site
-
Wollongong, New South Wales, Australien, 2500
- GSK Investigational Site
-
-
Queensland
-
Benowa, Queensland, Australien, 4217
- GSK Investigational Site
-
Herston, Queensland, Australien, 4029
- GSK Investigational Site
-
-
South Australia
-
Ashford, South Australia, Australien, 5037
- GSK Investigational Site
-
-
Victoria
-
Box Hill, Victoria, Australien, 3128
- GSK Investigational Site
-
Heidelberg, Victoria, Australien, 3084
- GSK Investigational Site
-
Melbourne, Victoria, Australien, 3004
- GSK Investigational Site
-
-
Western Australia
-
Murdoch, Western Australia, Australien, 6150
- GSK Investigational Site
-
Nedlands, Western Australia, Australien, 6009
- GSK Investigational Site
-
-
-
-
-
Roeselare, Belgien, 8800
- GSK Investigational Site
-
-
Brussels Capital
-
Jette, Brussels Capital, Belgien, 1090
- GSK Investigational Site
-
Woluwé-Saint-Lambert, Brussels Capital, Belgien, 1200
- GSK Investigational Site
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, Belgien, 9000
- GSK Investigational Site
-
-
-
-
-
Joinville, Brasilien, 89201-260
- GSK Investigational Site
-
Natal, Brasilien, 59075-740
- GSK Investigational Site
-
Rio de Janeiro, Brasilien, 22775001
- GSK Investigational Site
-
São Paulo, Brasilien, 04537-080
- GSK Investigational Site
-
São Paulo, Brasilien, 05403-000
- GSK Investigational Site
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasilien, 90035-903
- GSK Investigational Site
-
-
Santa Catarina
-
Florianópolis, Santa Catarina, Brasilien, 88020-210
- GSK Investigational Site
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- GSK Investigational Site
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- GSK Investigational Site
-
Toronto, Ontario, Canada, M4N 3M5
- GSK Investigational Site
-
-
Quebec
-
Montreal, Quebec, Canada, H4J 1C5
- GSK Investigational Site
-
-
-
-
-
Bournemouth, Det Forenede Kongerige, BH7 7DW
- GSK Investigational Site
-
Cardiff, Det Forenede Kongerige, CF14 4XW
- GSK Investigational Site
-
Dundee, Det Forenede Kongerige, DD1 9SY
- GSK Investigational Site
-
Leicester, Det Forenede Kongerige, LE1 5WW
- GSK Investigational Site
-
London, Det Forenede Kongerige, W12 0NN
- GSK Investigational Site
-
Stoke-on-Trent, Det Forenede Kongerige, ST4 6QG
- GSK Investigational Site
-
Sutton, Det Forenede Kongerige, SM2 5PT
- GSK Investigational Site
-
-
-
-
Arizona
-
Yuma, Arizona, Forenede Stater, 85364
- GSK Investigational Site
-
-
Kansas
-
Mission, Kansas, Forenede Stater, 66205-2005
- GSK Investigational Site
-
-
North Carolina
-
Denver, North Carolina, Forenede Stater, 80128
- GSK Investigational Site
-
-
Ohio
-
Blue Ash, Ohio, Forenede Stater, 45242-5665
- GSK Investigational Site
-
-
Texas
-
Tyler, Texas, Forenede Stater, 75702
- GSK Investigational Site
-
-
Virginia
-
Roanoke, Virginia, Forenede Stater, 24014
- GSK Investigational Site
-
-
-
-
-
Amiens, Frankrig, 80054
- GSK Investigational Site
-
Caen, Frankrig, 14033
- GSK Investigational Site
-
Nice, Frankrig, 06200
- GSK Investigational Site
-
Paris, Frankrig, 75651
- GSK Investigational Site
-
Rennes, Frankrig, 35033
- GSK Investigational Site
-
-
-
-
-
Athens, Grækenland, 11528
- GSK Investigational Site
-
Thessaloniki, Grækenland, 54007
- GSK Investigational Site
-
-
East Macedonia and Thrace
-
Alexandroupoli, East Macedonia and Thrace, Grækenland, 681 00
- GSK Investigational Site
-
-
-
-
-
Groningen, Holland, 9713 GZ
- GSK Investigational Site
-
-
South Holland
-
Dordrecht, South Holland, Holland, 3318 AT
- GSK Investigational Site
-
-
-
-
-
Jerusalem, Israel, 91120
- GSK Investigational Site
-
Kfar Saba, Israel, 44281
- GSK Investigational Site
-
Ramat Gan, Israel, 52621
- GSK Investigational Site
-
Tel Aviv, Israel, 64239
- GSK Investigational Site
-
-
-
-
-
Bergamo, Italien, 24127
- GSK Investigational Site
-
Bologna, Italien, 40138
- GSK Investigational Site
-
Brescia, Italien, 25123
- GSK Investigational Site
-
Catania, Italien, 95123
- GSK Investigational Site
-
Meldola FC, Italien, 47014
- GSK Investigational Site
-
Milan, Italien, 20133
- GSK Investigational Site
-
Ravenna, Italien, 48121
- GSK Investigational Site
-
Roma, Italien, 00168
- GSK Investigational Site
-
Siena, Italien, 53100
- GSK Investigational Site
-
Torino, Italien, 10126
- GSK Investigational Site
-
-
-
-
-
Aichi, Japan, 467-8602
- GSK Investigational Site
-
Aichi, Japan, 441-8570
- GSK Investigational Site
-
Aomori, Japan, 030-8553
- GSK Investigational Site
-
Ehime, Japan, 790-8524
- GSK Investigational Site
-
Fukuoka, Japan, 806-8501
- GSK Investigational Site
-
Fukuoka, Japan, 807-8555
- GSK Investigational Site
-
Fukuoka, Japan, 810-8563
- GSK Investigational Site
-
Fukuoka, Japan, 815-8555
- GSK Investigational Site
-
Gifu, Japan, 503-8502
- GSK Investigational Site
-
Gunma, Japan, 377-0280
- GSK Investigational Site
-
Hyōgo, Japan, 670-8540
- GSK Investigational Site
-
Kanagawa, Japan, 247-8533
- GSK Investigational Site
-
Kanagawa, Japan, 221-0855
- GSK Investigational Site
-
Kochi, Japan, 781-8555
- GSK Investigational Site
-
Nagano, Japan, 392-8510
- GSK Investigational Site
-
Okayama, Japan, 701-1192
- GSK Investigational Site
-
Osaka, Japan, 545-8586
- GSK Investigational Site
-
Osaka, Japan, 530-0012
- GSK Investigational Site
-
Shizuoka, Japan, 411-8777
- GSK Investigational Site
-
-
-
-
-
Beijing, Kina, 100191
- GSK Investigational Site
-
Beijing, Kina, 100020
- GSK Investigational Site
-
Changchun, Kina, 130012
- GSK Investigational Site
-
Guangzhou, Kina, 510060
- GSK Investigational Site
-
Guangzhou, Kina, 510515
- GSK Investigational Site
-
Hangzhou, Kina, 310003
- GSK Investigational Site
-
Jinan, Kina, 250012
- GSK Investigational Site
-
Nanjing, Kina, 210008
- GSK Investigational Site
-
Shenyang, Kina, 110001
- GSK Investigational Site
-
Suzhou, Kina, 215006
- GSK Investigational Site
-
Tianjin, Kina, 300020
- GSK Investigational Site
-
Zhengzhou, Kina, 450052
- GSK Investigational Site
-
-
-
-
-
Christchurch, New Zealand, 8011
- GSK Investigational Site
-
Dunedin, New Zealand, 9054
- GSK Investigational Site
-
Takapuna Auckland, New Zealand, 1309
- GSK Investigational Site
-
Wellington, New Zealand, 6021
- GSK Investigational Site
-
-
-
-
-
Chorzów, Polen, 41-500
- GSK Investigational Site
-
Krakow, Polen, 30510
- GSK Investigational Site
-
Lodz, Polen, 93-513
- GSK Investigational Site
-
Lublin, Polen, 20-081
- GSK Investigational Site
-
Lublin, Polen, 20-090
- GSK Investigational Site
-
Nowy Sącz, Polen, 33-300
- GSK Investigational Site
-
Poznan, Polen, 60-569
- GSK Investigational Site
-
Warsaw, Polen, 02-781
- GSK Investigational Site
-
-
-
-
-
Moscow, Rusland, 125284
- GSK Investigational Site
-
Nizhny Novgorod, Rusland, 603126
- GSK Investigational Site
-
Novosibirsk, Rusland, 630087
- GSK Investigational Site
-
Saint Petersburg, Rusland, 191024
- GSK Investigational Site
-
Saint Petersburg, Rusland, 197 089
- GSK Investigational Site
-
Samara, Rusland, 443021
- GSK Investigational Site
-
Saratov, Rusland, 410028
- GSK Investigational Site
-
Ufa, Rusland, 450083
- GSK Investigational Site
-
-
-
-
-
Barcelona, Spanien, 08035
- GSK Investigational Site
-
Barcelona, Spanien, 08916
- GSK Investigational Site
-
Cáceres, Spanien, 10003
- GSK Investigational Site
-
Gijón, Spanien, 33394
- GSK Investigational Site
-
L'Hospitalet de Llobrega, Spanien, 08908
- GSK Investigational Site
-
MOstoles Madrid, Spanien, 28933
- GSK Investigational Site
-
Madrid, Spanien, 28007
- GSK Investigational Site
-
Madrid, Spanien, 31008
- GSK Investigational Site
-
Murcia, Spanien, 30008
- GSK Investigational Site
-
PamplonaNavarra, Spanien, 31008
- GSK Investigational Site
-
Pozuelo de AlarcOn Madr, Spanien, 28223
- GSK Investigational Site
-
Salamanca, Spanien, 37007
- GSK Investigational Site
-
-
-
-
-
Pusan, Sydkorea, 49241
- GSK Investigational Site
-
Seongnam-si Gyeonggi-do, Sydkorea, 13620
- GSK Investigational Site
-
Seoul, Sydkorea, 06351
- GSK Investigational Site
-
Seoul, Sydkorea, 06591
- GSK Investigational Site
-
Ulsan, Sydkorea, 44033
- GSK Investigational Site
-
-
-
-
-
Brno, Tjekkiet, 625 00
- GSK Investigational Site
-
Hradec Králové, Tjekkiet, 500 05
- GSK Investigational Site
-
Ostrava, Tjekkiet, 708 52
- GSK Investigational Site
-
Prague, Tjekkiet, 128 08
- GSK Investigational Site
-
-
-
-
-
Cologne, Tyskland, 50937
- GSK Investigational Site
-
-
Baden-Wurttemberg
-
Ulm, Baden-Wurttemberg, Tyskland, 89081
- GSK Investigational Site
-
-
Bavaria
-
München, Bavaria, Tyskland, 81377
- GSK Investigational Site
-
Würzburg, Bavaria, Tyskland, 97080
- GSK Investigational Site
-
-
North Rhine-Westphalia
-
Düsseldorf, North Rhine-Westphalia, Tyskland, 40225
- GSK Investigational Site
-
-
Thuringia
-
Jena, Thuringia, Tyskland, 07747
- GSK Investigational Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Confirmed diagnosis of multiple myeloma as defined by the International Myeloma Working Group (IMWG) criteria.
-
Previously treated with at least 1 prior line of multiple myeloma (MM) therapy, and must have documented disease progression during or after their most recent therapy.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
-
Must have at least 1 aspect of measurable disease, defined as one of the following;
- Urine M-protein excretion >=200 mg per 24-hour, or
- Serum M-protein concentration >=0.5 grams per deciliter (g/dL), or
- Serum free light chain (FLC) assay: involved FLC level >=10 mg per dL (>=100 mg per liter) and an abnormal serum free light chain ratio (<0.26 or >1.65).
-
All prior treatment-related toxicities (defined by National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI-CTCAE] version 5.0) must be <=Grade 1 at the time of enrollment, except for alopecia.
-
Adequate organ function
Exclusion Criteria:
- Intolerant to daratumumab.
- Refractory to daratumumab or any other anti-CD38 therapy (defined as progressive disease during treatment with anti-CD38 therapy, or within 60 days of completing that treatment).
- Intolerant to bortezomib, or refractory to bortezomib (defined as progressive disease during treatment with a bortezomib-containing regimen of 1.3 mg/m^2 twice weekly, or within 60 days of completing that treatment). Note: participants with progressive disease during treatment with a weekly bortezomib regimen are allowed.
- Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain.
- Prior treatment with anti-B-cell maturation antigen (anti-BCMA) therapy.
- Prior allogenic stem cell transplant.
- Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions, including renal, liver, cardiovascular, or certain prior malignancies.
- Corneal epithelial disease.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Belantamab mafodotin og Bortezomib plus Dexamethason (arm A)
|
Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate Proteasome Inhibitor Synthetic glucocorticoid with anti-tumor activity |
|
Aktiv komparator: Daratumumab og Bortezomib plus dexamethason (arm B)
|
Proteasome Inhibitor Synthetic glucocorticoid with anti-tumor activity Anti-cluster of differentiation 38 [CD-38] monoclonal antibody |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-free Survival (PFS)
Tidsramme: Up to approximately 41 months
|
PFS is defined as time from randomization until earliest date of disease progression (PD), determined by Independent Review Committee (IRC), according to the International Myeloma Working Group (IMWG) Response Criteria, or death due to any cause. PD= increase of >=25% from lowest value in >=1 of following (serum M-protein [absolute increase >=0.5 grams per deciliter {g/dL}]; serum M-protein increase >=1g/dL [when lowest M-protein >=5g/dL]; urine M-protein [absolute increase >=200 milligrams per 24 hours {mg/24h}]; participants without measurable serum & urine M-protein levels, difference between involved & uninvolved serum free light chains (sFLC) levels [absolute increase >10mg/dL]; appearance of new lesion,>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of >1 lesion, or >=50% increase in longest diameter of previous lesion >1 centimeter (cm) in short axis. |
Up to approximately 41 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Antal deltagere med unormale øjenfund på oftalmisk undersøgelse
Tidsramme: Op til 73 måneder
|
Op til 73 måneder
|
|
|
Complete Response Rate (CRR)
Tidsramme: Up to 73 months
|
CRR is defined as percentage of participants with a confirmed complete response or better. |
Up to 73 months
|
|
Overall Response Rate (ORR)
Tidsramme: Up to 73 months
|
ORR is defined as percentage of participants with a confirmed partial response or better. |
Up to 73 months
|
|
Clinical Benefit Rate (CBR)
Tidsramme: Up to 73 months
|
CBR is defined as percentage of participants with a confirmed minimal response (MR) or better |
Up to 73 months
|
|
Duration of Response (DoR)
Tidsramme: Up to 73 months
|
DOR is defined as time from first documented evidence of partial response or better until first documented progression or death, whichever occurs first. |
Up to 73 months
|
|
Time to Response (TTR)
Tidsramme: Up to 73 months
|
TTR is defined as time from the date of randomization and the first documented evidence of response (PR or better) among participants who achieve partial response or better. |
Up to 73 months
|
|
Time to Progression (TTP)
Tidsramme: Up to 73 months
|
TTP is defined as time from the date of randomization until the earliest date of documented date of disease progression or death, whichever occurs first. |
Up to 73 months
|
|
Overall Survival (OS)
Tidsramme: Up to 73 months
|
OS is defined as time from the date of randomization until the date of death due to any cause. |
Up to 73 months
|
|
Progression-free Survival on Subsequent Line of Therapy (PFS2)
Tidsramme: Up to 73 months
|
Progression-free survival on subsequent line of therapy is defined as time from randomization to disease progression after initiation of new anti-myeloma therapy or death from any cause, whichever occurs first. If disease progression after new antimyeloma therapy cannot be measured, a PFS event is defined as the date of discontinuation of new anti-myeloma therapy, or death from any cause, whichever is earlier. |
Up to 73 months
|
|
Minimal Residual Disease (MRD) Negativity Rate
Tidsramme: Up to 73 months
|
Minimal Residual Disease (MRD) negativity rate is defined as the percentage of participants who are MRD negative status by next generation sequencing (NGS). |
Up to 73 months
|
|
Number of Participants With Adverse Events (AEs)
Tidsramme: Up to 73 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. |
Up to 73 months
|
|
Number of Participants With Clinically Significant Changes in Hematology Parameters
Tidsramme: Up to 73 months
|
Blood samples will be collected for the analysis of hematology parameters. |
Up to 73 months
|
|
Number of Participants With Clinically Significant Changes in Clinical Chemistry
Tidsramme: Up to 73 months
|
Blood samples will be collected for the analysis of clinical chemistry parameters. |
Up to 73 months
|
|
Number of Participants With Clinically Significant Changes in Urine Dipstick
Tidsramme: Up to 73 months
|
Urine samples will be collected for the urine dipstick analysis. |
Up to 73 months
|
|
Plasma Concentrations of Belantamab Mafodotin (Total Antibody) at Indicated Time Points
Tidsramme: Up to 73 months
|
Blood samples will be collected for PK analysis of belantamab mafodotin. |
Up to 73 months
|
|
Plasma Concentrations of Belantamab Mafodotin (ADC) at Indicated Time Points
Tidsramme: Up to 73 months
|
Blood samples will be collected for PK analysis of belantamab mafodotin. |
Up to 73 months
|
|
Plasma Concentrations of Monomethyl Auristatin-F With a Cysteine Linker (Cys-mcMMAF) at Indicated Time Points
Tidsramme: Up to 73 months
|
Blood samples will be collected for PK analysis of belantamab mafodotin. |
Up to 73 months
|
|
Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
Tidsramme: Up to 73 months
|
Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be tested in screening assay, and positive samples will be further characterized for antibody titers. |
Up to 73 months
|
|
Titers of ADAs Against Belantamab Mafodotin
Tidsramme: Up to 73 months
|
Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be to be further tested in screening assay, and positive samples will be further to be characterized for antibody titers. |
Up to 73 months
|
|
Number of Participants With Maximum Post-baseline Change From Baseline in Individual Items of Patient-Reported Outcome Version of the Common Term Criteria for Adverse Events (PRO-CTCAE)
Tidsramme: Up to 73 months
|
The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE. |
Up to 73 months
|
|
Change From Baseline in Health Related Quality of Life (HRQoL) as Measured by EuropeanOrganization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30)
Tidsramme: Up to 73 months
|
The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning [PF], role functioning [RF], cognitive functioning [CF], emotional functioning [EF] and social functioning [SF]), three symptom scales (fatigue, pain and nausea/vomiting [N/V]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss [AL] and financial difficulties [FD]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. |
Up to 73 months
|
|
Change From Baseline in HRQoL as Measured by EORTC IL52
Tidsramme: Up to 73 months
|
The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. For the EORTC IL52, disease symptoms domain of the QLQ-MY20 will be used for bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to100. A high score for disease symptoms represents a high level of symptomatology or problems. A high score represents a high/healthy level of functioning. |
Up to 73 months
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: GSK Clinical Trials, GlaxoSmithKline
Publikationer og nyttige links
Generelle publikationer
- Mateos MV, Trudel S, Quach H, Robak P, Beksac M, Pour L, Hus M, Kim K, Zherebtsova V, Delimpasi S, Jelinek T, Ward C, Ho PJ, Vorobyev V, Pitombeira de Lacerda M, Aparecida-Martinez G, Spicka I, Radocha J, Cavo M, Cerchione C, Fu C, Suzuki K, Rogers R, Phillips-Jones A, Wang Z, Baig H, Wilkes J, Zhou XL, Lewis E, Eccersley L, Sule N, Paka P, Opalinska JB, Mukhopadhyay P, Hungria V, Dimopoulos MA. Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials. Blood Adv. 2025 Nov 25;9(22):5708-5719. doi: 10.1182/bloodadvances.2025016949.
- Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Martinez GA, Sureda Balari A, Sandhu I, Cerchione C, Ganly P, Dimopoulos MA, Fu C, Garg M, Abdallah AO, Gatt ME, Oriol Rocafiguera A, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Ficek J, Mantero A, Pirooz N, Varghese S, Lee J, McKeown A, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Mukhopadhyay P, Nielsen J, Opalinska J, Mateos MV; DREAMM-7 study investigators. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial. Lancet Oncol. 2025 Aug;26(8):1067-1080. doi: 10.1016/S1470-2045(25)00330-4. Epub 2025 Jul 15.
- Hungria V, Hus M, Fu C, Zherebtsova V, Ward C, Ho PJ, Mikulski D, Muronova L, Cerchione C, Loubert A, Bunod L, M'Hari M, Pirooz N, Rogers R, Lin CP, Roy-Ghanta S, Opalinska JB, Purser M, McKeown A, McNamara S, Baig H, Eccersley L, Pompilus F, Mateos MV; DREAMM-7 trial study group. Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial. Lancet Haematol. 2025 Aug;12(8):e599-e610. doi: 10.1016/S2352-3026(25)00163-2. Epub 2025 Jul 15.
- Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Ribas de Almeida AC, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Aparecida Martinez G, Sureda Balari AM, Sandhu I, Cerchione C, Ganly P, Dimopoulos M, Fu C, Garg M, Abdallah AO, Oriol A, Gatt ME, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Pirooz N, McKeown A, McNamara S, Zhou X, Nichols M, Lewis E, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Opalinska J, Mateos MV; DREAMM-7 Investigators. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024 Aug 1;391(5):393-407. doi: 10.1056/NEJMoa2405090. Epub 2024 Jun 1.
- Zhang X, Xing X, Wang Z, Wang K, Hua Y, Zhang L, Dong X. Threshold Price of Belantamab for Relapsed/Refractory Multiple Myeloma in China: A Cost-Effectiveness Analysis. Pharmacoecon Open. 2026 Sep 11. doi: 10.1007/s41669-026-00681-8. Online ahead of print.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Karsygdomme
- Hjerte-kar-sygdomme
- Neoplasmer
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Hæmatologiske sygdomme
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Neoplasmer, Plasmacelle
- Hæmostatiske lidelser
- Paraproteinæmier
- Blodproteinforstyrrelser
- Hæmoragiske lidelser
- Hemiske og lymfatiske sygdomme
- Myelomatose
- Organiske kemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Polycykliske forbindelser
- Uorganiske kemikalier
- Gravidier
- Graviditet
- Steroider
- SMUSED-RING-forbindelser
- Steroider, fluoreret
- Gravideretrioler
- Boronsyrer
- Syrer, ikke -carboxylisk
- Syrer
- Borforbindelser
- Pyraziner
- Bortezomib
- Dexamethason
- Daratumumab
- Belantamab mafodotin
Andre undersøgelses-id-numre
- 207503
- 2018 (U.S. NIH-bevilling/kontrakt)
- 2018-003993-29 (Registry Identifier: EudraCT (EU))
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .